AI Article Synopsis

  • The study aimed to evaluate the effectiveness and safety of a new ¹⁸F-labeled amyloid tracer, ¹⁸F-FC119S, in diagnosing Alzheimer's disease (AD).
  • A total of 105 participants were involved, including AD patients, those with other dementias, and healthy controls, with tests like cognitive assessments, ¹⁸F-FC119S PET scans, and brain MRIs conducted to compare the diagnostic performance against existing methods.
  • Results showed that ¹⁸F-FC119S PET had a sensitivity of 92% and specificity of 84% for detecting AD, outperforming other diagnostic tools like ¹⁸F-FDG PET and MRI, with no significant adverse effects

Article Abstract

Background And Purpose: The aim of this study was to determine the diagnostic performance and safety of a new ¹⁸F-labeled amyloid tracer, ¹⁸F-FC119S.

Methods: This study prospectively recruited 105 participants, comprising 53 with Alzheimer's disease (AD) patients, 16 patients with dementia other than AD (non-AD), and 36 healthy controls (HCs). In the first screening visit, the Seoul Neuropsychological Screening Battery cognitive function test was given to the dementia group, while HC subjects completed the Korean version of the Mini Mental State Examination. Individuals underwent ¹⁸F-FC119S PET, ¹⁸F-fluorodeoxyglucose (FDG) PET, and brain MRI. The diagnostic performance of ¹⁸F-FC119S PET for AD was compared to a historical control (comprising previously reported and currently used amyloid-beta PET agents), ¹⁸F-FDG PET, and MRI. The standardized uptake value (SUV) ratio (ratio of the cerebral cortical SUV to the cerebellar SUV) was measured for each PET data set to provide semiquantitative analysis. All adverse effects during the clinical trial periods were monitored.

Results: Visual assessments of the ¹⁸F-FC119S PET data revealed a sensitivity of 92% and a specificity of 84% in detecting AD. ¹⁸F-FC119S PET demonstrated equivalent or better diagnostic performance for AD detection than the historical control, ¹⁸F-FDG PET (sensitivity of 80.0% and specificity of 76.0%), and MRI (sensitivity of 98.0% and specificity of 50.0%). The SUV ratios differed significantly between AD patients and the other groups, at 1.44±0.17 (mean±SD) for AD, 1.24±0.09 for non-AD, and 1.21±0.08 for HC. No clinically significant adverse effects occurred during the trial periods.

Conclusions: ¹⁸F-FC119S PET provides high sensitivity and specificity in detecting AD and therefore may be considered a useful diagnostic tool for AD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974833PMC
http://dx.doi.org/10.3988/jcn.2020.16.1.131DOI Listing

Publication Analysis

Top Keywords

¹⁸f-fc119s pet
20
diagnostic performance
12
pet
10
clinical trial
8
historical control
8
¹⁸f-fdg pet
8
pet data
8
adverse effects
8
diagnostic
5
¹⁸f-fc119s
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!